ESMO Guidelines for Anal Cancer
Management Test Bank Questions
and Answers
What were the results of the NCI9673 study regarding nivolumab in advanced anal
cancer? - 24% response rate (19% partial response, 5% complete response) and 47%
stable disease.
What were the median PFS and OS for nivolumab in the NCI9673 study? - Median PFS
was 4.1 months and median OS was 11.5 months.
What is the first-line treatment for eligible patients with Stage IV anal cancer? -
Carboplatin-paclitaxel.
What are the second-line treatment options for Stage IV anal cancer? - Cisplatin-5-FU,
carboplatin, doxorubicin, taxane, irinotecan ± cetuximab or combinations.
When may PD-L1 inhibitors be considered in anal cancer treatment? - In patients who
have progressed on first-line therapy in clinical trials.
What is not required for the use of PD-1/PD-L1 inhibitors in metastatic anal cancer? -
Microsatellite instability/mismatch repair testing.
What is the aim of the proposed treatment algorithm for advanced anal cancer? - To
guide management decisions based on patient eligibility and treatment response.
What is the significance of HPV proteins E6 and E7 in anal cancer? - They promote
recruitment of tumor-infiltrating lymphocytes (TILs), triggering an anti-cancer immune
response.
What is the prognosis for patients with local failures following CRT? - Salvage surgery is
only feasible for a proportion of such patients.
What is recommended as a new standard of care for patients with ChT-naive advanced
anal cancer? - Carboplatin in combination with paclitaxel.
What are alternative treatment options for patients with ChT-naive advanced anal
cancer? - Cisplatin in combination with 5-FU/capecitabine, carboplatin, or docetaxel-
based combinations.
,When might PD-L1 inhibitors be considered for patients with advanced anal cancer? - In
patients who have progressed on first-line therapy in clinical trials.
What biomarker is overexpressed in high-risk HPV-related cervical cancers and may
help identify SCCs harboring HPV DNA? - p16.
How does moderate-strong p16 staining affect treatment response in anal cancer
patients? - Patients may achieve a better response to CRT and have a lower risk of
relapse compared to those with absent or weak staining.
What is the significance of assessing tumor-infiltrating lymphocytes (TILs) in anal
cancer? - It adds prognostic information regarding HPV status following CRT and
highlights the importance of the immune response.
What is the recommended follow-up schedule for patients in complete remission from
anal cancer? - Every 3-6 months for 2 years, then every 6-12 months until 5 years.
What clinical examinations are included in the follow-up for anal cancer patients? -
Clinical examination including DRE and palpation of the inguinal lymph nodes.
What imaging techniques are suggested for assessing suspicious lesions in anal cancer
patients? - MRI and/or PET, with biopsy if possible.
What does data from the ACT II study suggest about relapses after 3 years in anal
cancer patients? - Very few (<1%) relapses occur after 3 years, so extended imaging
surveillance is not recommended.
What annual surveillance is recommended after tumor regression is confirmed at 3 and
6 months? - Annual CT scans at 12, 24, and 36 months.
What long-term effects can disease and treatment have on anal cancer survivors? -
They can affect anorectal and sexual function, as well as continence and urgency.
What correlation exists between acute and late adverse events during IMRT and
treatment outcomes? - They correlate with RT doses to the small bowel and anterior
pelvic contents.
What is the role of the anal cancer MDT in patient follow-up? - To consider follow-up in
all patients within a protocol-driven program.
What is a major obstacle in establishing clinically relevant biomarkers for anal cancer? -
The lack of sufficient data from clinical trials due to small patient numbers.
What is the purpose of the Clinical Practice Guideline developed by the authors? - To
provide recommendations based on the latest evidence for the treatment of advanced
anal cancer.
, What is the significance of the ESMO standard operating procedures in the
development of clinical guidelines? - They ensure that guidelines are developed based
on relevant literature and expert consensus.
What does the term 'protocol-driven programme' refer to in the context of anal cancer
follow-up? - A structured approach to patient follow-up as guided by the anal cancer
multidisciplinary team.
What is the funding source for the preparation of the clinical guidelines? - No external
funding; production costs covered by ESMO from central funds.
What is the implication of sparse data on long-term quality of life (QoL) outcomes in
anal cancer survivors? - It indicates a need for more research on the impact of disease
and treatment on functional outcomes.
What is the recommendation regarding the use of anoscopy or proctoscopy in follow-up
care? - It is an additional option but may be poorly tolerated and painful after CRT.
What is the potential benefit of personalized medicine in the treatment of anal cancer? -
It may lead to more tailored and effective treatment strategies based on individual
patient characteristics.
What is the overall conclusion regarding the need for further research in anal cancer
treatment? - More research is needed to establish effective biomarkers and improve
treatment outcomes.
What are common side effects of pelvic radiotherapy in women? - Menopause and loss
of fertility.
How does pelvic radiotherapy affect male fertility? - It may also affect male fertility.
What should be clearly provided to patients regarding treatment for anal cancer? -
Information on treatment-related side effects, particularly regarding anorectal and
sexual functioning.
What outcomes should be investigated after treatment for anal cancer? - Long-term
function and quality of life (QoL).
What type of questionnaire has been developed for anal cancer? - An anal cancer-
specific quality of life questionnaire.
What is the challenge in treating anal cancer? - Balancing treatment intensity
(radiotherapy dose and volume) with long-term side effects.
Management Test Bank Questions
and Answers
What were the results of the NCI9673 study regarding nivolumab in advanced anal
cancer? - 24% response rate (19% partial response, 5% complete response) and 47%
stable disease.
What were the median PFS and OS for nivolumab in the NCI9673 study? - Median PFS
was 4.1 months and median OS was 11.5 months.
What is the first-line treatment for eligible patients with Stage IV anal cancer? -
Carboplatin-paclitaxel.
What are the second-line treatment options for Stage IV anal cancer? - Cisplatin-5-FU,
carboplatin, doxorubicin, taxane, irinotecan ± cetuximab or combinations.
When may PD-L1 inhibitors be considered in anal cancer treatment? - In patients who
have progressed on first-line therapy in clinical trials.
What is not required for the use of PD-1/PD-L1 inhibitors in metastatic anal cancer? -
Microsatellite instability/mismatch repair testing.
What is the aim of the proposed treatment algorithm for advanced anal cancer? - To
guide management decisions based on patient eligibility and treatment response.
What is the significance of HPV proteins E6 and E7 in anal cancer? - They promote
recruitment of tumor-infiltrating lymphocytes (TILs), triggering an anti-cancer immune
response.
What is the prognosis for patients with local failures following CRT? - Salvage surgery is
only feasible for a proportion of such patients.
What is recommended as a new standard of care for patients with ChT-naive advanced
anal cancer? - Carboplatin in combination with paclitaxel.
What are alternative treatment options for patients with ChT-naive advanced anal
cancer? - Cisplatin in combination with 5-FU/capecitabine, carboplatin, or docetaxel-
based combinations.
,When might PD-L1 inhibitors be considered for patients with advanced anal cancer? - In
patients who have progressed on first-line therapy in clinical trials.
What biomarker is overexpressed in high-risk HPV-related cervical cancers and may
help identify SCCs harboring HPV DNA? - p16.
How does moderate-strong p16 staining affect treatment response in anal cancer
patients? - Patients may achieve a better response to CRT and have a lower risk of
relapse compared to those with absent or weak staining.
What is the significance of assessing tumor-infiltrating lymphocytes (TILs) in anal
cancer? - It adds prognostic information regarding HPV status following CRT and
highlights the importance of the immune response.
What is the recommended follow-up schedule for patients in complete remission from
anal cancer? - Every 3-6 months for 2 years, then every 6-12 months until 5 years.
What clinical examinations are included in the follow-up for anal cancer patients? -
Clinical examination including DRE and palpation of the inguinal lymph nodes.
What imaging techniques are suggested for assessing suspicious lesions in anal cancer
patients? - MRI and/or PET, with biopsy if possible.
What does data from the ACT II study suggest about relapses after 3 years in anal
cancer patients? - Very few (<1%) relapses occur after 3 years, so extended imaging
surveillance is not recommended.
What annual surveillance is recommended after tumor regression is confirmed at 3 and
6 months? - Annual CT scans at 12, 24, and 36 months.
What long-term effects can disease and treatment have on anal cancer survivors? -
They can affect anorectal and sexual function, as well as continence and urgency.
What correlation exists between acute and late adverse events during IMRT and
treatment outcomes? - They correlate with RT doses to the small bowel and anterior
pelvic contents.
What is the role of the anal cancer MDT in patient follow-up? - To consider follow-up in
all patients within a protocol-driven program.
What is a major obstacle in establishing clinically relevant biomarkers for anal cancer? -
The lack of sufficient data from clinical trials due to small patient numbers.
What is the purpose of the Clinical Practice Guideline developed by the authors? - To
provide recommendations based on the latest evidence for the treatment of advanced
anal cancer.
, What is the significance of the ESMO standard operating procedures in the
development of clinical guidelines? - They ensure that guidelines are developed based
on relevant literature and expert consensus.
What does the term 'protocol-driven programme' refer to in the context of anal cancer
follow-up? - A structured approach to patient follow-up as guided by the anal cancer
multidisciplinary team.
What is the funding source for the preparation of the clinical guidelines? - No external
funding; production costs covered by ESMO from central funds.
What is the implication of sparse data on long-term quality of life (QoL) outcomes in
anal cancer survivors? - It indicates a need for more research on the impact of disease
and treatment on functional outcomes.
What is the recommendation regarding the use of anoscopy or proctoscopy in follow-up
care? - It is an additional option but may be poorly tolerated and painful after CRT.
What is the potential benefit of personalized medicine in the treatment of anal cancer? -
It may lead to more tailored and effective treatment strategies based on individual
patient characteristics.
What is the overall conclusion regarding the need for further research in anal cancer
treatment? - More research is needed to establish effective biomarkers and improve
treatment outcomes.
What are common side effects of pelvic radiotherapy in women? - Menopause and loss
of fertility.
How does pelvic radiotherapy affect male fertility? - It may also affect male fertility.
What should be clearly provided to patients regarding treatment for anal cancer? -
Information on treatment-related side effects, particularly regarding anorectal and
sexual functioning.
What outcomes should be investigated after treatment for anal cancer? - Long-term
function and quality of life (QoL).
What type of questionnaire has been developed for anal cancer? - An anal cancer-
specific quality of life questionnaire.
What is the challenge in treating anal cancer? - Balancing treatment intensity
(radiotherapy dose and volume) with long-term side effects.
